Aankondiging • Jun 17
StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders StemRIM Inc. announced that a patent will soon be registered in Australia for the application related to the novel treatment of cartilage disorders (namely traumatic cartilage defect of joint, osteoarthritis, and osteochondritis dissecans) utilizing the peptide drug developed from the "Regeneration-Inducing MedicineTM" development candidate Redasemtide (HMGB1 fragment peptide). Title of Invention Therapeutic agent for cartilage disorder. Region Australia. Application No. 2019367943. Registration No. To be determined . Applicant StemRIM, Osaka University This patent is intended to expand the indications for Redasemtide, which is currently under development, and believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (namely traumatic cartilage defect of joint, osteoarthritis, and osteochondritis dissecans) in Australia. Cartilage disorders cause pain and functional impairment of the joint due to damage or degeneration of cartilage. Because cartilage has limited selfrepair capacity, such disorders tend to become chronic and progressive. It has been confirmed that intravenous administration of Redasemtide mobilizes bone marrow-derived mesenchymal stem cells (MSCs) into the bloodstream and promotes their accumulation at sites of tissue injury. Through this mechanism, Redasemtide is considered to facilitate tissue repair and regeneration in areas of cartilage damage within the knee joint. With its intravenous route of administration, which imposes a relatively low burden on patients, Redasemtide is anticipated to serve as a highly useful therapeutic option in clinical practice. Aankondiging • Jun 16
StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic Steatohepatitis StemRIM Inc. announced that a medical use patent for the Regeneration-Inducing MedicineTM development candidate, Redasemtide, indicated for fatty liver and non-alcoholic steatohepatitis, will soon be registered in Russia. Title of Invention: Therapeutic drug for fatty liver and non-alcoholic steatohepatitis. Region: Russia. Application No.: 2024111536. Registration No.: To be determined. Applicant: StemRIM Inc., Osaka University, Niigata University. This patent is intended to expand the indications for Redasemtide, which is currently under development. Fatty liver is a condition in which excess fat accumulates in the liver. Non-alcoholic steatohepatitis (NASH) is a progressive fatty liver disease caused by factors other than alcohol consumption characterized by inflammation and fibrosis of the liver, which, if left untreated, can lead to cirrhosis or liver cancer. Both fatty liver and NASH are expected to see an increase in patient numbers due to the rising prevalence of obesity and diabetes. However, there are currently no effective drug treatments available, and dietary and exercise therapy remain the main approaches. The development of new therapeutic drugs and regenerative medicine is urgently needed. The impact on the financial performance for the fiscal year ending July 31, 2026, is insignificant. The terms "fatty liver" and "non-alcoholic steatohepatitis (NASH)" have been renamed to "steatotic liver disease (SLD)" and "metabolic dysfunction associated steatohepatitis (MASH)," respectively. New Risk • Mar 11
New major risk - Revenue and earnings growth Earnings have declined by 30% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 30% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change). New Risk • Jan 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.3b net loss in 3 years). Share price has been volatile over the past 3 months (5.4% average weekly change). Aankondiging • Jan 06
StemRIM to Report Q2, 2026 Results on Mar 11, 2026 StemRIM announced that they will report Q2, 2026 results on Mar 11, 2026 New Risk • Dec 15
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.5b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.3b net loss in 3 years). Market cap is less than US$100m (JP¥15.5b market cap, or US$99.9m). Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Founder, Chief Scientific Officer & Director Katsuto Tamai was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Aankondiging • Oct 28
StemRIM to Report Q1, 2026 Results on Dec 10, 2025 StemRIM announced that they will report Q1, 2026 results on Dec 10, 2025 Aankondiging • Sep 10
StemRIM, Annual General Meeting, Oct 22, 2025 StemRIM, Annual General Meeting, Oct 22, 2025. Aankondiging • Aug 09
StemRIM to Report Fiscal Year 2025 Results on Sep 10, 2025 StemRIM announced that they will report fiscal year 2025 results on Sep 10, 2025 Aankondiging • Jun 03
StemRIM to Report Q3, 2025 Results on Jun 11, 2025 StemRIM announced that they will report Q3, 2025 results on Jun 11, 2025 Board Change • May 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Outside Director Noriko Sawai was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Apr 02
StemRIM Inc. Announces the Interim Analysis Results for the Global Phase 2B Clinical Trial in Patients with Acute Ischemic Stroke StemRIM Inc. announced that the interim analysis results for the global Phase 2b clinical trial of Redasemtide, which was previously out-licensed from company to Shionogi & Co. Ltd. for the treatment of acute ischemic stroke (AIS). This clinical trial is being conducted in 18 countries worldwide, including Japan, the United States, and Europe, to evaluate the efficacy and safety of Redasemtide in AIS patients who are not eligible for endovascular recanalization therapy. The trial consists of 3 cohorts, with patients receiving Redasemtide at a dose of 1.5 mg/kg, Redasemtide at an dose of 0.75 mg/kg, or a placebo for 5 days. With advances in medical technology, the treatment paradigm for AIS has undergone significant changes, and the proportion of patients eligible for treatment with endovascular recanalisation therapy has been rapidly increasing. To adapt to these changes and enable broader patient access to Redasemtide after its market approval, conducted an interim futility analysis by dose group in AIS patients for whom endovascular reperfusion therapy could not be performed. In this interim analysis, a predefined futility criterion was established. For each dose group, if the results met the futility criterion compared to the placebo group, the study would be discontinued for that group; if not, it would be continued. To maintain blinding, an independent evaluation committee assessed the data and provided recommendations to Shionogi regarding the continuation or discontinuation of each dose group. While Redasemtide (1.5 mg/kg) group was originally selected as the expected efficacious dose at the start of the trial, the inclusion of Redasemtide (0.75 mg/kg) group was mandated by regulatory authorities. The outcome of this interim analysis falls within the anticipated range. With the discontinuation of the lower dose group, the required number of subjects will be reduced, and further progress in the study is expected moving forward. Going forward, the target number of subjects will be redefined to include the additional cohort; however, the overall study duration is not expected to be extended. The results of this interim analysis hold significant importance in the clinical development of this investigational drug for AIS, and the company are very pleased with the outcome. At this time, there is no impact on the financial results for the fiscal year ending July 31, 2025. New Risk • Mar 11
New major risk - Revenue and earnings growth Earnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change). Aankondiging • Jan 30
StemRIM to Report Q2, 2025 Results on Mar 12, 2025 StemRIM announced that they will report Q2, 2025 results on Mar 12, 2025 New Risk • Dec 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change). Aankondiging • Oct 29
StemRIM to Report Q1, 2025 Results on Dec 11, 2024 StemRIM announced that they will report Q1, 2025 results on Dec 11, 2024 Aankondiging • Sep 11
StemRIM, Annual General Meeting, Oct 30, 2024 StemRIM, Annual General Meeting, Oct 30, 2024. Aankondiging • Jul 27
StemRIM to Report Fiscal Year 2024 Results on Sep 11, 2024 StemRIM announced that they will report fiscal year 2024 results on Sep 11, 2024 New Risk • Jun 17
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.7b net loss in 3 years). Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Aankondiging • Apr 03
StemRIM to Report Q3, 2024 Results on Jun 12, 2024 StemRIM announced that they will report Q3, 2024 results on Jun 12, 2024 Price Target Changed • Mar 14
Price target decreased by 25% to JP¥900 Down from JP¥1,200, the current price target is provided by 1 analyst. New target price is 57% above last closing price of JP¥574. Stock is down 47% over the past year. The company is forecast to post a net loss per share of JP¥21.20 compared to earnings per share of JP¥2.80 last year. Aankondiging • Mar 13
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy StemRIM Inc. announced that a clinical trial plan for Phase 2 investigator-initiated clinical trial, targeting ischemic cardiomyopathy using Redasemtide, has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) by Osaka University. Redasemtide is a drug under development that has been licensed out to Shionogi & Co. Ltd. This clinical trial will be initiated with the submission of this clinical trial plan notification. This clinical trial will be conducted as an investigator-initiated clinical trials at Osaka University Hospital and several other facilities. The main objective of this clinical trial is to evaluate the efficacy and safety of Redasemtide in patients with ischemic cardiomyopath who have undergone coronary artery bypass grafting. This clinical trial will evaluate various cardiac function tests such as echocardiography at 52 weeks after treatment with either Redasemtide or placebo (10 patients each) for 5 days. Redasemtide are a completely new concept in medicine that induces functional regeneration of organs and tissues damaged by injury or disease. The ectodermal mesenchymal stem cells induced by administration of Redasemtide can differentiate into diverse tissues and are expected to be effective in a variety of disease areas, including ischemic cardiomyiology. Furthermore, as it is administered through intravenous infusion and does not involve the use of live cells, this pharmaceutical product is industrially producible. Unlike traditional regenerative medical products that utilize live cells, it avoids quality control issues during manufacturing and product transport. It is anticipated to have a cost advantage and widespread adoption due to its simple administration method. In clinical trials to date, the safety and efficacy of Redasemtide have been confirmed in dystrophic epidermolysis bullosa (add additional Phase 2 clinical trial ongoing at Osaka University Hospital and other institutions), acute ischemic stroke (global Phase 2b clinical trial ongoing in Japan, the United States, and Europe), knee osteoarthritis (Phase 2 investigator-initiatedclinical trial completed at Hirosaki University Hospital), and chronic liver disease (Phase 2 investigator-in initiated clinical trial l completed at Niigata University Medical and Dental Hospital). Ischemic cardiomyopathy will be the 5th indication for Redasemtide in a Phase 2 clinical trial. The impact on the financial performance for the fiscal year ending July 31, 2024, is nothing. Nevertheless, believe it contributes to the medium to long-term improvement of overall performance. Aankondiging • Feb 01
StemRIM Inc. Announces Patent Registration (Russia) for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders StemRIM Inc. announced that a patent has been registered in Russia for the application related to the novel treatment of cartilage disorders (traumatic cartilage deficiency syndrome, osteoarthritis, disseverance osteochondritis, etc.) utilizing the peptide drug developed from the "Regeneration-Inducing MedicineTM" development candidate Redasemtide (HMGB1 fragment peptide). Title of Invention: Therapeutic agent for traumatic cartilage deficiency syndrome, osteearthritis, disseverance Osteochondritis. Region.: Russia. Application No. 2021114359. Registration No. To be determined. Applicant. StemRIM, Osaka University. This patent is intended to expand the indications for Redasemtide, which is currently under development, and believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (traumatic cart cartilage deficiency syndrome, osteOarthritis, disseverance boneochondritis, etc.) in Russia. To date, the company have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents. The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant. Aankondiging • Jan 28
StemRIM to Report Q2, 2024 Results on Mar 13, 2024 StemRIM announced that they will report Q2, 2024 results on Mar 13, 2024 Aankondiging • Oct 29
StemRIM to Report Q1, 2024 Results on Dec 13, 2023 StemRIM announced that they will report Q1, 2024 results on Dec 13, 2023 Aankondiging • Sep 13
StemRIM, Annual General Meeting, Oct 25, 2023 StemRIM, Annual General Meeting, Oct 25, 2023. Aankondiging • Sep 05
StemRIM Announces Patent Registration (China) for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction StemRIM announces that a medical use patent for the "Regeneration- Inducing MedicineTM" development candidate, Redasemtide, indicated for cardiomyopathy, old myocardial infarction, and chronic heart failure associated with them, will soon be registered in China. This patent is intended to expand the indications for Redasemtide, which is currently underdevelopment, and believe that the granting of this patent will ensure the possibility of developing a drug for cardiomyopathy, old myocardial infarction, and chronic heart failure inChina. To date, it have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents. The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant. Aankondiging • Aug 01
StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke (Japan) StemRIM Inc. announced that Shionogi & Co. Ltd. has notified that the first patient has been administered of the global late phase 2 clinical trial for Redasemtide targeting acute ischemic stroke in Japan. This clinical trial is a global late phase 2 clinical trial, planned to be conducted in 19 countriesworldwide, including Japan, the United States, and Europe. It aims to evaluate the effectiveness and safety of administering Redasemtide to 627 patients with acute ischemic stroke, aged 18 years and above, within 25 hours of symptom onset. Aankondiging • Jul 26
StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and China StemRIM Inc. announced the commencement, from July 25, 2023, of a global late Phase 2 clinical trial for Redasemtide in patients with acute ischemic stroke in the Europe and China. Shionogi &Co. Ltd. submitted the Clinical Trial Plan Notification for the global Phase 2 clinical trial to the European Medicines Agency on March 31, 2023, and to the National Medical Products Administration in China on April 28, 2023. Originally, a global Phase 3 trial was planned, but a global late Phase 2 trial was chosen instead for dose setting. The trial has already been underway in Japan and the United States, and it has just started in Europe and China. This development is progressing as planned and is not expected to have any impact on the financial performance for the fiscal year ending July 31, 2023. However, the company believe that it will contribute to the improvement of its performance in the medium to long term. Aankondiging • Jul 22
StemRIM to Report Fiscal Year 2023 Results on Sep 13, 2023 StemRIM announced that they will report fiscal year 2023 results on Sep 13, 2023 Aankondiging • Jun 19
StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023 StemRIM provided earnings guidance for the year ending July 31, 2023. The company expects operating revenue of ¥2,350 million, operating income of ¥146 million, net income of ¥170 million or ¥2.84 per share. Reported Earnings • Jun 16
Third quarter 2023 earnings released: EPS: JP¥31.50 (vs JP¥8.31 loss in 3Q 2022) Third quarter 2023 results: EPS: JP¥31.50 (up from JP¥8.31 loss in 3Q 2022). Net income: JP¥1.80b (up JP¥2.29b from 3Q 2022). Revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Japan are expected to grow by 9.1%. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Aankondiging • Jan 06
StemRIM to Report Q2, 2023 Results on Mar 08, 2023 StemRIM announced that they will report Q2, 2023 results on Mar 08, 2023 Price Target Changed • Nov 16
Price target increased to JP¥1,240 Up from JP¥1,000, the current price target is provided by 1 analyst. New target price is 35% above last closing price of JP¥920. Stock is up 68% over the past year. The company posted a net loss per share of JP¥32.91 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Tadahiro Nagai was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 11
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Tadahiro Nagai was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 02
Full year 2022 earnings released: JP¥32.91 loss per share (vs JP¥10.02 loss in FY 2021) Full year 2022 results: JP¥32.91 loss per share (further deteriorated from JP¥10.02 loss in FY 2021). Net loss: JP¥1.95b (loss widened 235% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Aankondiging • Oct 29
StemRIM to Report Q1, 2023 Results on Dec 14, 2022 StemRIM announced that they will report Q1, 2023 results on Dec 14, 2022 Aankondiging • Sep 10
StemRIM, Annual General Meeting, Oct 26, 2022 StemRIM, Annual General Meeting, Oct 26, 2022. Reported Earnings • Sep 10
Full year 2022 earnings released: JP¥32.91 loss per share (vs JP¥10.02 loss in FY 2021) Full year 2022 results: JP¥32.91 loss per share (further deteriorated from JP¥10.02 loss in FY 2021). Net loss: JP¥1.95b (loss widened 235% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Aankondiging • Aug 07
StemRIM to Report Fiscal Year 2022 Results on Sep 08, 2022 StemRIM announced that they will report fiscal year 2022 results on Sep 08, 2022 Reported Earnings • Jun 11
Third quarter 2022 earnings released: JP¥8.31 loss per share (vs JP¥8.82 loss in 3Q 2021) Third quarter 2022 results: JP¥8.31 loss per share (up from JP¥8.82 loss in 3Q 2021). Revenue: JP¥0 (flat on 3Q 2021). Net loss: JP¥493.0m (loss narrowed 4.8% from 3Q 2021). Profit margin: (in line with 3Q 2021). Price Target Changed • Apr 27
Price target increased to JP¥1,400 Up from JP¥1,200, the current price target is provided by 1 analyst. New target price is 91% above last closing price of JP¥733. Stock is down 8.4% over the past year. The company posted a net loss per share of JP¥10.02 last year. Aankondiging • Jan 28
StemRIM to Report Q2, 2022 Results on Mar 10, 2022 StemRIM announced that they will report Q2, 2022 results on Mar 10, 2022 Reported Earnings • Dec 14
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations First quarter 2022 results: JP¥8.31 loss per share (down from JP¥4.58 loss in 1Q 2021). Revenue: JP¥22.0m (down 90% from 1Q 2021). Net loss: JP¥490.0m (loss widened 88% from 1Q 2021). Revenue was in line with analyst estimates. Reported Earnings • Nov 02
Full year 2021 earnings released: JP¥10.02 loss per share (vs JP¥6.43 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: JP¥1.40b (down 33% from FY 2020). Net loss: JP¥582.0m (down 268% from profit in FY 2020). Price Target Changed • Oct 01
Price target increased to JP¥1,000 Up from JP¥900, the current price target is provided by 1 analyst. New target price is 47% above last closing price of JP¥682. Stock is down 20% over the past year. Reported Earnings • Sep 15
Full year 2021 earnings released: JP¥10.02 loss per share (vs JP¥6.43 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: JP¥1.40b (down 33% from FY 2020). Net loss: JP¥582.0m (down 268% from profit in FY 2020). Price Target Changed • Apr 27
Price target decreased to JP¥1,250 Down from JP¥1,350, the current price target is provided by 1 analyst. New target price is 58% above last closing price of JP¥792. Stock is up 70% over the past year. Is New 90 Day High Low • Feb 22
New 90-day high: JP¥830 The company is up 1.0% from its price of JP¥825 on 24 November 2020. The Japanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period. Aankondiging • Feb 04
StemRIM to Report Q2, 2021 Results on Mar 11, 2021 StemRIM announced that they will report Q2, 2021 results on Mar 11, 2021 Is New 90 Day High Low • Dec 22
New 90-day low: JP¥624 The company is down 34% from its price of JP¥950 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. Is New 90 Day High Low • Dec 07
New 90-day low: JP¥751 The company is down 14% from its price of JP¥873 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period. Aankondiging • Aug 03
StemRIM to Report Fiscal Year 2020 Results on Sep 11, 2020 StemRIM announced that they will report fiscal year 2020 results on Sep 11, 2020 
